AAV vectors containing either scramble shRNA or shRNA against GnT-V were administered into the left ventricle, followed by intraperitoneal injection of STZ to assess the role of GnT-V in controlling diabetic cardiomyopathy. This evidence concerns the gene MGAT5 and diabetic cardiomyopathy.